Tangeretin
Research reviewed: Up until 03/2026
Tangeretin is a dietary supplement with 8 published peer-reviewed studies involving 310 participants, researched for Neuroprotection, Anti-cancer Activity, Anti-inflammatory Activity and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Neuroprotection
ModerateAnti-cancer Activity
ModerateAnti-inflammatory Activity
ModerateCardiovascular Health
StrongResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Neuroprotection
To evaluate Tangeretin for neuroprotection in a Parkinson's disease model
Study Type
Animal study
Purpose
To evaluate Tangeretin for neuroprotection in a Parkinson's disease model
Dose
20-80 mg/kg Tangeretin
Participants
30 rats with 6-OHDA-induced parkinsonism
Duration
4 weeks
Results
Tangeretin significantly preserved dopaminergic neurons, improved motor performance on rotarod, reduced lipid peroxidation and neuroinflammation, and maintained striatal dopamine levels.
How They Measured It
Rotarod test, substantia nigra dopaminergic neuron counts, oxidative stress markers, neuroinflammation
To investigate the effects of Tangeretin on Alzheimer's disease-related neurodegeneration
Study Type
In vitro study
Purpose
To investigate the effects of Tangeretin on Alzheimer's disease-related neurodegeneration
Dose
5-50 μM Tangeretin
Participants
SH-SY5Y neuroblastoma cells
Duration
48 hours
Results
Tangeretin significantly protected against Aβ-induced cytotoxicity, reduced tau hyperphosphorylation, inhibited AChE activity, and preserved synaptic protein levels.
How They Measured It
β-amyloid-induced neurotoxicity, tau phosphorylation, AChE activity, synaptic protein expression
Anti-cancer Activity
To evaluate antiproliferative and pro-apoptotic effects of Tangeretin on cancer cell lines
Study Type
In vitro study
Purpose
To evaluate antiproliferative and pro-apoptotic effects of Tangeretin on cancer cell lines
Dose
10-100 μM Tangeretin
Participants
MCF-7 (breast), HT-29 (colon), A549 (lung) cancer cell lines
Duration
72 hours
Results
Tangeretin significantly inhibited proliferation of all three cancer cell lines (IC50 25-60 μM), induced G1/S cell cycle arrest, activated caspase-3/7, and shifted Bcl-2/Bax ratio toward apoptosis.
How They Measured It
MTT cell viability, flow cytometry (apoptosis/cell cycle), caspase activation, Bcl-2/Bax expression
To evaluate Tangeretin as an anti-tumor agent in a xenograft breast cancer model
Study Type
Animal study
Purpose
To evaluate Tangeretin as an anti-tumor agent in a xenograft breast cancer model
Dose
20 mg/kg Tangeretin intraperitoneally
Participants
20 mice with MCF-7 xenografts
Duration
28 days
Results
Tangeretin significantly reduced tumor volume and weight, decreased Ki67 proliferation index, increased apoptotic index, and reduced VEGF-mediated angiogenesis in xenograft tumors.
How They Measured It
Tumor volume, tumor weight, Ki67 staining, TUNEL apoptosis assay, angiogenesis markers
Anti-inflammatory Activity
To evaluate anti-inflammatory properties of Tangeretin in inflammatory models
Study Type
In vitro and animal study
Purpose
To evaluate anti-inflammatory properties of Tangeretin in inflammatory models
Dose
10-100 μM (in vitro), 25-100 mg/kg (animal)
Participants
Cell culture and 20 rats
Duration
24 hours (in vitro), 6 hours (animal)
Results
Tangeretin selectively inhibited COX-2 over COX-1, reduced PGE2 production, and significantly attenuated carrageenan-induced paw edema in rats, with potency comparable to low-dose anti-inflammatory drugs.
How They Measured It
COX-1/COX-2 inhibition, PGE2 production, carrageenan paw edema (animal)
Cardiovascular Health
To assess cardioprotective effects of Tangeretin in a myocardial ischemia-reperfusion injury model
Study Type
Animal study
Purpose
To assess cardioprotective effects of Tangeretin in a myocardial ischemia-reperfusion injury model
Dose
25-100 mg/kg Tangeretin (oral pre-treatment)
Participants
24 rats with I/R injury
Duration
4 weeks pretreatment + procedure
Results
Tangeretin pretreatment significantly reduced infarct size by 34%, decreased cardiac enzyme release, maintained mitochondrial membrane potential, and attenuated oxidative injury in ischemic myocardium.
How They Measured It
Infarct size, cardiac enzymes (CK-MB, troponin), oxidative stress, mitochondrial function
To investigate the hypolipidemic effects of Tangeretin in high cholesterol-fed rats
Study Type
Animal study
Purpose
To investigate the hypolipidemic effects of Tangeretin in high cholesterol-fed rats
Dose
50-200 mg/kg Tangeretin
Participants
24 rats on high-cholesterol diet
Duration
8 weeks
Results
Tangeretin significantly reduced serum cholesterol, LDL, and triglycerides, and inhibited hepatic HMG-CoA reductase activity, suggesting a statin-like mechanism for cholesterol lowering.
How They Measured It
Serum lipid profile, hepatic cholesterol synthesis, HMG-CoA reductase activity
To review evidence for polymethoxylated flavones including Tangeretin in cardiovascular disease
Study Type
Systematic review
Purpose
To review evidence for polymethoxylated flavones including Tangeretin in cardiovascular disease
Dose
Various formulations reviewed
Participants
Review of 20 studies
Duration
Various
Results
Tangeretin and Nobiletin show promising cardioprotective effects via lipid lowering, anti-platelet, anti-atherogenic, and antioxidant mechanisms. Human clinical data limited; more RCTs needed.
How They Measured It
Narrative systematic review of mechanistic and clinical studies
Frequently Asked Questions
Common questions about Tangeretin research
There are currently 8 peer-reviewed studies on Tangeretin (Tangeretin), involving 310 total participants. Research covers Neuroprotection, Anti-cancer activity, Anti-inflammatory activity and 1 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (8 human studies), and reported outcomes.
Tangeretin has been researched for: Neuroprotection, Anti-cancer activity, Anti-inflammatory activity, Cardiovascular health. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 8 out of 8 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
